About
Tyrell J. Rivers, Ph.D., has served as a member of ADC Therapeutics' board of directors since June 2018. He is a Vice President within AstraZeneca's Corporate Development & Ventures group, where he has been since 2014, and from 2009 to 2014 was at MedImmune Ventures specializing in biotechnology investing. He also serves on the board of Cellectis. Dr. Rivers holds a B.S. in chemical engineering from the Massachusetts Institute of Technology, an M.S. in engineering and a Ph.D. in chemical engineering from the University of Texas at Austin, and an M.B.A. from New York University's Stern School of Business.
Roles
ADC Therapeutics SA
Director · Current role
June 2018–present
AstraZeneca
Vice President, Corporate Development & Ventures
2014 - present
MedImmune Ventures
Biotechnology investing
2009 - 2014
External Roles
Cellectis S.A.
Director
—
Director Compensation
FY 2025Fees earned or paid in cash
$0
ComponentDid not receive non-employee director compensation for fiscal 2025 (reported as nil in the proxy Director Compensation table)
Total
$0
Also at ADC Therapeutics SA
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.